Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | PYGB | P11216 | 6/20 | 0.35 |
| ▸ | PYGL | P06737 | 3/20 | 0.35 |
| ▸ | PYGM | P11217 | 2/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15797632 | 1.00 | AKR1B1 (0.48) | AKR1B1PYGBPYGLPYGMSLC5A1 | |
| SCHEMBL28090068 | 0.83 | TDP1 (0.47) | — | |
| SCHEMBL10771475 | 0.82 | LGALS9 (0.39) | PYGB | |
| SCHEMBL30843273 | 0.78 | LGALS9 (0.40) | — | |
| SCHEMBL27897377 | 0.77 | AKR1B1 (0.48) | AKR1B1PYGB | |
| SCHEMBL28664605 | 0.74 | PYGB (0.45) | PYGBPYGLPYGM | |
| SCHEMBL27731941 | 0.74 | PYGB (0.45) | PYGBPYGLPYGM | |
| SCHEMBL9862851 | 0.74 | PYGB (0.45) | PYGBPYGLPYGM | |
| SCHEMBL1842511 | 0.74 | PYGB (0.45) | PYGBPYGLPYGM | |
| SCHEMBL1842510 | 0.74 | PYGB (0.45) | PYGBPYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032403-A1 | COMPOSITIONS FOR TREATING PERIODONTAL DISEASES | GR BIOSYSTEMS INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240342203-A1 | COMPOSITIONS FOR ORAL CANCER OR AN OROPHARYNGEAL CANCER | GR BIOSYSTEMS, INC. | 2024-10-17 | — | — | US | disclosed |
| US-12016871-B2 | Compositions for oral cancer or an oropharyngeal cancer | GR BIOSYSTEMS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016871-B2 | Compositions for oral cancer or an oropharyngeal cancer | MMP9, MMP1, MMP7 | AKR1B1 2395/4885PYGB 4241/4885PYGL 3762/4885 |
| US-20250032403-A1 | COMPOSITIONS FOR TREATING PERIODONTAL DISEASES | MMP1, MMP9, MMP13 | AKR1B1 3315/4885PYGB 1319/4885PYGL 770/4885 |
| US-20240342203-A1 | COMPOSITIONS FOR ORAL CANCER OR AN OROPHARYNGEAL CANCER | MMP9, MMP1, MMP7 | AKR1B1 2395/4885PYGB 4241/4885PYGL 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.